Between the two companies there are now many millions of dollars that have been put up and set aside for something. You don’t just gather up over $10 million for fun. There is a plan on how all that money will be used.
RXMD failed to execute or show any significant revenue increases on the approx. 13 domestic state distribution pharma licenses, so the speculation that they are going international with the potential to enter the Asian pharmaceutical market is really a stretch IMO.
Market Data 
Markets 
AI
